𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination targeted therapy in advanced renal cell carcinoma

✍ Scribed by Jeffrey Sosman; Igor Puzanov

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
245 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Targeting mTOR in renal cell carcinoma
Targeting mTOR in renal cell carcinoma
✍ Gary R. Hudes πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 1 views
Sequential therapy in renal cell carcino
Sequential therapy in renal cell carcinoma
✍ Bernard Escudier; Marine Gross Goupil; Christophe Massard; Karim Fizazi πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 1 views
Targeted therapy of renal cell carcinoma
Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg
✍ Stefan Bauer; Jeannette C. Oosterwijk-Wakka; Nicole Adrian; Egbert Oosterwijk; E πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 477 KB

## Abstract Immunotherapeutic targeting of G250/Carbonic anhydrase IX (CA‐IX) represents a promising strategy for treatment of renal cell carcinoma (RCC). The well characterized human‐mouse chimeric G250 (cG250) antibody has been shown in human studies to specifically enrich in CA‐IX positive tumor

CCNU, vinblastine, and delalutin therapy
CCNU, vinblastine, and delalutin therapy in renal cell carcinoma
✍ Vosika, Gerald J. ;Ryan, Michael J. ;Fortuny, Ignacio A. ;Meyer, Cynthia ;Kiang, πŸ“‚ Article πŸ“… 1978 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Advanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current stud